Core Insights - GE HealthCare Technologies Inc. (GEHC) has received FDA 510(k) clearance for its Photonova Spectra, an advanced photon-counting computed tomography (PCCT) system aimed at enhancing diagnostic precision and workflow efficiency [1][4] - The Photonova Spectra system utilizes proprietary Deep Silicon detector technology, offering a flexible platform for various clinical applications [1][11] - GE HealthCare is collaborating with institutions like the University of Wisconsin-Madison and Stanford Medicine to explore new applications in quantitative imaging and spectral biomarker discovery [2] Product Features - Photonova Spectra employs photon-counting CT technology, allowing for higher spatial and spectral resolution compared to conventional CT systems [10] - The system's 8-bin energy resolution enables precise differentiation of materials such as iodine, calcium, and fat, enhancing disease detection capabilities [12] - Integrated accelerated computing powered by NVIDIA allows Photonova Spectra to manage up to 50 times more data than traditional CT systems, ensuring efficient workflow [13] Market Position and Financial Impact - Following the FDA clearance announcement, GEHC's shares increased by 2.9%, with a market capitalization of $31.78 billion [5][8] - The FDA clearance strengthens GEHC's leadership in next-generation imaging technologies and expands its premium product portfolio, supporting long-term service agreements and recurring revenue streams [6] - The photon counting CT market is projected to grow from $0.5 billion in 2026 at a CAGR of 29.4% through 2035, driven by regulatory approvals and rising demand for advanced diagnostic imaging [15]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-40976 SPECTAIRE HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 98-1578608 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-40976 SPECTAIRE HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 98-1578608 (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40976 Spectaire Holdings Inc. (Exact name of Registrant as specified in its Charter) Delaware 98-1578608 (State or other jurisdiction ...

(Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-40976 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Spectaire Holdings Inc. (Exact name of registrant as specified in its charter) | Delawar | | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40976 PERCEPTION CAPITAL CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 98-1578608 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Commission File Number 001-40976 PERCEPTION CAPITAL CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 98-1578608 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 315 Lake Street East, Suite 301 Wayzata, MN 55391 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40976 Perception Capital Corp. II | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | Cayman Islands | ...